跳至主要内容
临床试验/IRCT20110530006652N2
IRCT20110530006652N2已完成3 期

The effect of Oleoylethanolamide supplementation on peroxisome proliferator-activated receptor alpha gene expression, pyroptosis pathway genes (TLR4, TRIF, MYD88, NLRP3, Caspase 1, Caspase 8, IL1ß and IL18), lipopolysaccharide binding protein, metabolic parameters, and anthropometric indices in obese patients with non-alcoholic fatty liver disease

Tabriz University of Medical Sciences0 个研究点目标入组 74 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
74

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20 years 至 50 years(—)
性别
All

入选标准

  • Age between 20 to 50 years old
  • Body mass index (BMI) of 30 to 40 Kg/m2
  • Diagnosis of non-alcoholic fatty liver disease by a radiologist based on ultrasonography

排除标准

  • Regular use of non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics and corticosteroids
  • Use of hormonal drugs, hepatotoxic drugs (such as Phenytoin, Amiodarone, Levothyroxine, Tamoxifene and Lithium), anti-hypertensive drugs, weight loss and lipid lowering drugs
  • Use of prebiotic and probiotic supplements, vitamins, minerals, antioxidants, and omega 3 supplements
  • Diagnosed pathological conditions affecting the liver such as liver transplantation, acute or chronic hepatic impairment, viral hepatitis, cystic fibrosis, Haemochromatosis, Wilson's disease, Alpha-1 antitrypsin deficiency, and acute systemic disease
  • Diagnosed thyroid disorders
  • Diagnosed kidney diseases
  • Diagnosed gastrointestinal diseases (e.g. Celiac disease)
  • Diagnosed diabetes
  • Diagnosed heart failure
  • Diagnosed autoimmune diseases
  • Diagnosed malignancies
  • Diagnosed severe psychological disorders
  • Pregnancy and lactation

研究者

相似试验